Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $38.56

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been given an average rating of “Moderate Buy” by the eleven analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $38.56.

A number of research firms have commented on FDMT. Leerink Partners cut their target price on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. BMO Capital Markets downgraded shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the company from $40.00 to $15.00 in a research report on Monday, January 13th. Royal Bank of Canada cut their target price on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. Chardan Capital reissued a “buy” rating and set a $39.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Finally, Morgan Stanley cut their price objective on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research report on Monday, January 13th.

Institutional Trading of 4D Molecular Therapeutics

Several large investors have recently bought and sold shares of FDMT. Assenagon Asset Management S.A. grew its position in 4D Molecular Therapeutics by 238.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company’s stock worth $16,684,000 after purchasing an additional 1,087,147 shares during the last quarter. Braidwell LP grew its position in 4D Molecular Therapeutics by 231.7% during the 3rd quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock worth $13,247,000 after purchasing an additional 855,990 shares during the last quarter. Redmile Group LLC grew its position in 4D Molecular Therapeutics by 17.6% during the 3rd quarter. Redmile Group LLC now owns 1,262,090 shares of the company’s stock worth $13,643,000 after purchasing an additional 188,655 shares during the last quarter. Novo Holdings A S grew its position in 4D Molecular Therapeutics by 7.1% during the 3rd quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock worth $16,215,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its stake in 4D Molecular Therapeutics by 652.7% during the 2nd quarter. Squarepoint Ops LLC now owns 110,041 shares of the company’s stock valued at $2,310,000 after acquiring an additional 95,422 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Performance

NASDAQ FDMT opened at $4.65 on Friday. The company has a market capitalization of $214.97 million, a price-to-earnings ratio of -1.63 and a beta of 2.81. The company’s 50-day simple moving average is $6.16 and its two-hundred day simple moving average is $10.51. 4D Molecular Therapeutics has a one year low of $4.43 and a one year high of $36.25.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.